This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma

This study has been completed.
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Regeneron Pharmaceuticals Identifier:
First received: May 14, 2004
Last updated: June 1, 2016
Last verified: June 2016

RATIONALE: VEGF Trap may stop the growth of solid tumors or non-Hodgkin's lymphoma by stopping blood flow to the tumor.

PURPOSE: This phase I trial is studying the side effects and best dose of intravenous VEGF Trap in treating patients with relapsed or refractory advanced solid tumors or non-Hodgkin's lymphoma.

Condition Intervention Phase
Cancer Biological: ziv-aflibercept Phase 1

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open Label, Sequential Cohort Dose-Escalation Safety, Tolerability and Pharmacokinetic Study of VEGF Trap Administered Intravenously in Patients With Advanced Solid Tumors or Lymphoma

Resource links provided by NLM:

Further study details as provided by Regeneron Pharmaceuticals:

Enrollment: 25
Study Start Date: January 2004
Primary Completion Date: May 2008 (Final data collection date for primary outcome measure)
Detailed Description:



  • Determine the safety and tolerability of intravenous VEGF Trap in patients with relapsed or refractory advanced solid tumors or non-Hodgkin's lymphoma.


  • Determine the maximum tolerated intravenous dose of this drug in these patients.
  • Determine the pharmacokinetics of this drug in these patients.
  • Determine the ability of this drug to bind circulating vascular endothelial growth factor in these patients.
  • Determine, preliminarily, the ability of this drug to alter tumor blood flow and tumor vascular permeability in these patients.
  • Determine whether antibodies to this drug develop in these patients.

OUTLINE: This is an open-label, dose-escalation, multicenter study.

Patients receive VEGF Trap IV over 1 hour on days 1 and 15 for a total of 2 doses.

Cohorts of 3-6 patients receive escalating doses of VEGF Trap until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, an additional 6 patients are treated at that dose level.

In the absence of dose-limiting toxicity, patients with stable disease or partial or complete remission may continue to receive VEGF Trap on a separate extension protocol.

Patients are followed at weeks 1, 3, and 7 and then at 3 months.

PROJECTED ACCRUAL: A maximum of 25 patients will be accrued for this study.


Ages Eligible for Study:   18 Years to 120 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  • Histologically confirmed diagnosis of one of the following:

    • Non-Hodgkin's lymphoma
    • Primary or metastatic solid tumor located, by radiography, in at least one of the following sites:

      • Liver
      • Soft tissue
      • Pelvis
      • Other site that is suitable for delayed contrast-enhanced MRI (e.g., peripheral lung field)
  • Relapsed or refractory (including unresectable) disease

    • Patients with solid tumors must have failed all curative chemotherapeutic regimens
    • Patients with non-Hodgkin's lymphoma must be refractory to at least 2 standard chemotherapeutic regimens and rituximab
  • Not amenable to available conventional therapies AND no standard therapy exists
  • Measurable disease
  • No prior or concurrent CNS metastases (brain or leptomeningeal)
  • No primary intracranial tumor by MRI or CT scan
  • No histologically confirmed squamous cell carcinoma of the lung



  • 18 and over

Performance status

  • ECOG 0-2

Life expectancy

  • Not specified


  • WBC ≥ 3,500/mm^3
  • Absolute neutrophil count ≥ 1,500/mm^3
  • Hemoglobin ≥ 9.0 g/dL
  • Platelet count ≥ 100,000/mm^3
  • No severe or uncontrolled hematologic condition


  • Bilirubin ≤1.5 times upper limit of normal (ULN)
  • AST and ALT ≤ 2.5 times ULN
  • PT and PTT normal
  • INR normal
  • Hepatitis B surface antigen negative
  • Hepatitis C antibody negative


  • Creatinine ≤ ULN
  • Urine protein/creatinine ratio ≤ 1
  • No severe or uncontrolled renal condition


  • No clinically significant acute electrocardiographic abnormalities
  • LVEF normal by echocardiogram or MUGA within the past 12 months if there was prior exposure to anthracyclines
  • No untreated or uncontrolled hypertension

    • No blood pressure > 150/100 mm Hg (despite treatment)
  • No isolated systolic hypertension (i.e., systolic blood pressure > 180 mm Hg on at least 2 determinations [on separate days] within the past 3 months)
  • No New York Heart Association class II - IV heart disease
  • No active coronary artery disease requiring acute medical management
  • No angina requiring acute medical management
  • No congestive heart failure requiring acute medical management
  • No ventricular arrhythmia requiring acute medical management
  • No stroke or transient ischemic event within the past 6 months
  • No prior or concurrent peripheral vascular disease

    • No angiographically or ultrasonographically documented arterial or venous occlusive event
    • No symptomatic claudication
  • No symptomatic orthostatic hypotension
  • No other severe or uncontrolled cardiovascular condition


  • No severe or uncontrolled pulmonary condition
  • No pulmonary embolism within the past 6 months


  • HIV negative
  • No severe or uncontrolled immunologic condition
  • No active current infection requiring antibiotics
  • No prior hypersensitivity reaction to any recombinant proteins, including VEGF Trap


  • No severe or uncontrolled gastrointestinal or musculoskeletal condition
  • No psychiatric condition or adverse social circumstance that would preclude study participation
  • No other condition that would preclude study participation
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective double-barrier contraception during and for 3 months after study treatment


Biologic therapy

  • See Disease Characteristics
  • No prior participation in a VEGF Trap, interleukin-1 Trap, or interleukin-4/13 Trap clinical trial
  • At least 3 weeks since prior immunotherapy and recovered
  • No concurrent epoetin alfa, filgrastim (G-CSF), or sargramostim (GM-CSF)


  • See Disease Characteristics
  • At least 3 weeks since prior chemotherapy and recovered

Endocrine therapy

  • No concurrent adrenal corticosteroids except low-dose replacement therapy
  • No concurrent systemic hormonal contraceptive agents


  • At least 3 weeks since prior radiotherapy and recovered


  • At least 3 weeks since prior major or laparoscopic surgery and recovered
  • More than 6 months since prior surgical procedure for correction or prophylaxis of peripheral vascular insufficiency or cerebral ischemic events


  • More than 30 days since prior investigational drugs
  • No concurrent anticoagulant or antiplatelet drugs (e.g., warfarin, heparin, or aspirin) other than low-dose (1 mg) warfarin for maintaining patency of venous access devices
  • No concurrent non-steroidal anti-inflammatory drugs, including cyclo-oxygenase-2 (COX-2) inhibitors
  • No other concurrent anticancer investigational agents
  • No other concurrent anticancer therapy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00083213

United States, New York
Memorial Sloan - Kettering Cancer Center
New York, New York, United States, 10021
Sponsors and Collaborators
Regeneron Pharmaceuticals
National Cancer Institute (NCI)
Principal Investigator: William P. Tew, MD Memorial Sloan Kettering Cancer Center
  More Information

Responsible Party: Regeneron Pharmaceuticals Identifier: NCT00083213     History of Changes
Other Study ID Numbers: REGENERON-VGFT-ST-0202
CDR0000360856 ( Registry Identifier: PDQ (Physician Data Query) )
Study First Received: May 14, 2004
Last Updated: June 1, 2016

Keywords provided by Regeneron Pharmaceuticals:
recurrent grade 1 follicular lymphoma
stage IV grade 1 follicular lymphoma
recurrent grade 2 follicular lymphoma
stage IV grade 2 follicular lymphoma
recurrent grade 3 follicular lymphoma
stage IV grade 3 follicular lymphoma
recurrent adult diffuse small cleaved cell lymphoma
stage IV adult diffuse small cleaved cell lymphoma
recurrent adult diffuse large cell lymphoma
stage IV adult diffuse large cell lymphoma
stage IV adult diffuse mixed cell lymphoma
recurrent adult diffuse mixed cell lymphoma
recurrent adult immunoblastic large cell lymphoma
stage IV adult immunoblastic large cell lymphoma
recurrent adult Burkitt lymphoma
stage IV adult Burkitt lymphoma
recurrent mantle cell lymphoma
stage IV mantle cell lymphoma
recurrent adult lymphoblastic lymphoma
stage IV adult lymphoblastic lymphoma
unspecified adult solid tumor, protocol specific
recurrent adult soft tissue sarcoma
recurrent adult primary liver cancer
advanced adult primary liver cancer
recurrent cervical cancer
stage IVA cervical cancer
stage IVB cervical cancer
fallopian tube cancer
ovarian sarcoma
recurrent ovarian epithelial cancer

Additional relevant MeSH terms:
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases processed this record on August 18, 2017